Daily Edition · Page 3

THE DAILY INDEX

Technology, AI, software, security, crypto and business

HEADLINES & LAUNCHES

TLDR AI

OPENAI'S BID TO ALLOW X-RATED TALK IS FREAKING OUT ITS OWN ADVISERS

OpenAI's plan to drop its ban on X-rated content sparked vigorous internal debate over the potential risks. The company is forging ahead with its erotica plans despite concerns from council members with backgrounds in fields like psychology and cognitive neuroscience. OpenAI staff have identified several risks, including the potential for compulsive use and emotional overreliance on the chatbot. The company has developed a plan to monitor for a range of potential long-term effects of adult mode. Adult mode's release has been delayed as OpenAI is currently prioritizing other products.

THE FIVE CATEGORIES OF WORLD MODELS

AMI Labs and World Labs both raised over $1B on "world models," but the term covers five distinct approaches: JEPA, spatial intelligence, learned simulation, physical AI infrastructure, and active inference. The sharpest result in the piece is V-JEPA 2, achieving zero-shot robot planning after training on just 62 hours of domain-specific data. Each approach solves a different subproblem, and the lines between them are expected to blur fast.

INTRODUCING ATTENTION RESIDUALS: RETHINKING DEPTH-WISE AGGREGATION

Residual connections have long relied on fixed uniform accumulation. Attention Residuals replace standard depth-wise recurrence with learned, input-dependent attention over preceding layers. It enables networks to selectively retrieve past representations, naturally mitigating dilution and hidden-state growth. Attention Residuals have been validated on the Kimi Linear architecture, demonstrating consistent downstream performance gains.

TECH BOSS USES AI AND CHATGPT TO CREATE CANCER VACCINE FOR HIS DYING DOG

Sydney data engineer Paul Conyngham used ChatGPT, AlphaFold protein modeling, and a $3,000 genomic sequencing of his dog Rosie's tumor to produce a half-page mRNA formula that UNSW's RNA Institute turned into a physical vaccine in under two months. One tumor shrank 75% after her first injection in December 2025, marking the first personalized cancer vaccine ever designed for a dog. The pipeline mirrors Moderna and Merck's ongoing human trials. UNSW researchers are now asking why the same approach isn't being applied more broadly to cancer patients.

TLDR IndexPage 3